Literature DB >> 9081637

Reserpine affects differentially the density of the vesicular monoamine transporter and dihydrotetrabenazine binding sites.

L Naudon1, R Raisman-Vozari, R H Edwards, I Leroux-Nicollet, D Peter, Y Liu, J Costentin.   

Abstract

We have studied the effect of a single injection of reserpine (5 mg/kg, s.c.) on the synaptic vesicle monoamine transporter (VMAT) density in the rat striatum, using two labelling procedures: radioimmunolabelling with an antibody against VMAT, and binding of the specific ligand [(3)H]dihydrotetrabenazine ([(3)H]TBZOH). In the rostral and medial striatum, the distribution of VMAT immunoreactivity displayed the highest density in the lateral subregions. In the caudal part of the striatum, VMAT immunoreactivity showed increasing density from dorsal to ventral subregions. The VMAT immunoreactivity was not altered 2 and 30 days after the reserpine injection, whereas [(3)H]TBZOH binding site density, measured on adjacent slices, showed a dramatic decrease at day 2 and a moderate recovery at day 30, suggesting that despite a persistent blockade of [(3)H]TBZOH binding sites, VMAT protein density was unchanged.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9081637     DOI: 10.1111/j.1460-9568.1996.tb01271.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  8 in total

Review 1.  VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse.

Authors:  Lee E Eiden; Eberhard Weihe
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

2.  Molecular imaging of cell transplantation in Parkinson's disease.

Authors:  Thierry Vander Borght
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04       Impact factor: 9.236

Review 3.  Levodopa in Parkinson's disease: neurotoxicity issue laid to rest?

Authors:  M G Murer; R Raisman-Vozari; O Gershanik
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

Review 4.  The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.

Authors:  Justin R Nickell; Kiran B Siripurapu; Ashish Vartak; Peter A Crooks; Linda P Dwoskin
Journal:  Adv Pharmacol       Date:  2014

5.  Adenosine Release Evoked by Short Electrical Stimulations in Striatal Brain Slices is Primarily Activity Dependent.

Authors:  Megan L Pajski; B Jill Venton
Journal:  ACS Chem Neurosci       Date:  2010-10-01       Impact factor: 4.418

6.  Long-lasting reflexive and nonreflexive pain responses in two mouse models of fibromyalgia-like condition.

Authors:  Beltrán Álvarez-Pérez; Meritxell Deulofeu; Judit Homs; Manuel Merlos; José Miguel Vela; Enrique Verdú; Pere Boadas-Vaello
Journal:  Sci Rep       Date:  2022-06-12       Impact factor: 4.996

7.  Consequences of dopaminergic denervation on the metabolic activity of the cortical neurons projecting to the subthalamic nucleus in the rat.

Authors:  Gaël Orieux; Chantal François; Jean Féger; Etienne C Hirsch
Journal:  J Neurosci       Date:  2002-10-01       Impact factor: 6.167

8.  Human methamphetamine pharmacokinetics simulated in the rat: behavioral and neurochemical effects of a 72-h binge.

Authors:  Ronald Kuczenski; David S Segal; William P Melega; Goran Lacan; Stanley J McCunney
Journal:  Neuropsychopharmacology       Date:  2009-07-01       Impact factor: 7.853

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.